Novavax said on Tuesday it signed a licensing ​agreement allowing Pfizer access to its technology that boosts immune ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Vaccine development is traditionally driven by financial return opportunities for investors, disease outbreaks, and a specific focus on emerging diseases. However, a new systematic, transparent, and ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...

Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...

A total of 22 mRNA vaccine development contracts totaling roughly $500 million have been canceled, the Department of Health and Human Services (HHS) announced Tuesday. The mRNA investments were part ...

Invivyd, Inc. has submitted a Citizen Petition to the FDA advocating for a new approach to the development of COVID-19 vaccines and monoclonal antibodies (mAbs) to restore public trust in health ...

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...